Novel diazepine-carbamate derivatives as dual-acting butyrylcholinesterase inhibitors and antioxidants for Alzheimer’s disease
- 11 October 2025
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 34 (12) , 2610-2627
Abstract
No abstract availableKeywords
Funding Information
- the University of Jordan
This publication has 38 references indexed in Scilit:
- Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluationEuropean Journal of Medicinal Chemistry, 2023
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Comparing the effects of organic cosolvents on acetylcholinesterase and butyrylcholinesterase activityAnalytical Biochemistry, 2022
- Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case studyComputational and Structural Biotechnology Journal, 2021
- Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffoldsChemico-Biological Interactions, 2019
- Comparative study of antioxidant activity and validated RP-HPTLC analysis of rutin in the leaves of different Acacia species grown in Saudi ArabiaSaudi Pharmaceutical Journal, 2017
- Privileged Diazepine Compounds and Their Emergence as Bromodomain InhibitorsChemistry & Biology, 2014
- Design and synthesis of novel 1,4-benzodiazepine derivatives and their biological evaluation as cholinesterase inhibitorsArchives of Pharmacal Research, 2012
- Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tanglesAnnals of Neurology, 1987
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961